MedTrace Logo

HDDO-1756 Bio Equivalence Study

NCT04755894 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2021-02-17

No results posted yet for this study

Summary

For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.

Conditions

  • Hyperlipidemias

Interventions

DRUG

HDDO-1756

single dose

DRUG

HDDO-17561/HDDO-17562

single dose

Sponsors & Collaborators

  • Hyundai Pharmaceutical Co., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2020-06-19
Completion
2020-07-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755894 on ClinicalTrials.gov